Omeros Corporation
OMERStock
$9.22+187.26%52W
Market Cap$685.39M
P/E—
Div yield—
Beta2.59
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-35.86%
Price vs S&P 500 (4W)8.79%
VGM Score55.02
Market Capitalization$685.39M
Earnings Surprise History
Q1 26-0.24est. -0.41
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
OMEROmeros Corporation | C | — | B | $9.22 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Omeros is a clinical-stage biopharmaceutical company developing targeted therapies for complement-mediated diseases and immunologic disorders. The company's lead candidate, narsoplimab, is a monoclonal antibody in clinical trials for rare immune-related conditions including thrombotic microangiopathy following stem cell transplantation and immunoglobulin nephropathy. Omeros also has programs targeting cancer and additional large-market immunologic indications.